keyword
MENU ▼
Read by QxMD icon Read
search

Onabotulinumtoxina

keyword
https://www.readbyqxmd.com/read/28639368/botulinum-toxin-state-of-the-art
#1
REVIEW
Joseph Jankovic
Botulinun neurotoxin (BoNT) has emerged as one of the most multipurpose therapeutic agents in modern medicine with more clinical applications than any other drug currently on the market. Initially developed in the treatment of strabismus and neurologic movement disorders, the use of botulinun neurotoxin has been expanding during the past 3 decades to include the treatment of a variety of ophthalmologic, gastrointestinal, urologic, orthopedic, dermatologic, dental, secretory, painful, cosmetic, and other conditions...
June 22, 2017: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/28625615/efficacy-and-safety-of-abobotulinumtoxina-dysport%C3%A2-for-the-treatment-of-hemiparesis-in-adults-with-upper-limb-spasticity-previously-treated-with-botulinum-toxin-sub-analysis-from-a-phase-3-randomized-controlled-trial
#2
Christina Marciniak, Peter McAllister, Heather Walker, Allison Brashear, Steven Edgley, Thierry Deltombe, Svetlana Khatkova, Marta Banach, Fatma Gul, Claire Vilain, Philippe Picaut, Anne-Sophie Grandoulier, Jean-Michel Gracies
OBJECTIVE: To assess the efficacy and safety of abobotulinumtoxinA in adults with upper limb spasticity previously treated with botulinum toxin A (BoNT-A). DESIGN: A post-hoc analysis from a Phase 3, prospective, double-blind, randomized, placebo-controlled study SETTING: 34 neurology or rehabilitation clinics in nine countries. PARTICIPANTS: Adults aged 18-80 years with hemiparesis, ≥6 months after stroke or traumatic brain injury. This analysis focused on a subgroup of subjects with previous onabotulinumtoxinA or incobotulinumtoxinA treatment (n=105 of 243 in the total trial population) in the affected limb...
June 15, 2017: PM & R: the Journal of Injury, Function, and Rehabilitation
https://www.readbyqxmd.com/read/28618692/re-different-number-of-intravesical-onabotulinumtoxina-injections-for-patients-with-refractory-detrusor-overactivity-do-not-affect-treatment-outcome-a-prospective-randomized-comparative-study
#3
https://www.readbyqxmd.com/read/28618691/re-more-than-15-years-of-experience-with-intradetrusor-onabotulinumtoxina-injections-for-treating-refractory-neurogenic-detrusor-overactivity-lessons-to-be-learned
#4
https://www.readbyqxmd.com/read/28614091/injectable-daxibotulinumtoxina-for-the-treatment-of-glabellar-lines-a-phase-2-randomized-dose-ranging-double-blind-multicenter-comparison-with-onabotulinumtoxina-and-placebo
#5
Jean Carruthers, Nowell Solish, Shannon Humphrey, Nathan Rosen, Channy Muhn, Vince Bertucci, Arthur Swift, Andrei Metelitsa, Roman G Rubio, Jacob Waugh, John Quiring, Gill Shears, Alastair Carruthers
BACKGROUND: Injectable daxibotulinumtoxinA (RT002) is an investigational botulinum toxin Type A in clinical development. It is formulated with a proprietary peptide and offers the potential of a longer acting neurotoxin therapy. OBJECTIVE: To compare the safety, efficacy, and duration of response of daxibotulinumtoxinA with onabotulinumtoxinA and placebo [www.clinicaltrials.gov NCT02303002]. METHODS: In this Phase 2, randomized, dose-ranging, parallel-group, double-blind, multicenter study, subjects with moderate or severe glabellar lines at maximum frown were randomly assigned to 20U, 40U, or 60U daxibotulinumtoxinA, 20U onabotulinumtoxinA, or placebo...
June 12, 2017: Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery [et Al.]
https://www.readbyqxmd.com/read/28566161/long-term-safety-of-repeated-high-doses-of-incobotulinumtoxina-injections-for-the-treatment-of-upper-and-lower-limb-spasticity-after-stroke
#6
Andrea Santamato, Francesco Panza, Domenico Intiso, Alessio Baricich, Alessandro Picelli, Nicola Smania, Francesca Fortunato, Davide Seripa, Pietro Fiore, Maurizio Ranieri
Current guidelines suggested a dosage up to 600units (U) of botulinum toxin type A (BoNT-A) (onabotulinumtoxinA or incobotulinumtoxinA) in reducing spastic hypertonia with low prevalence of complications, although a growing body of evidence showed efficacy with the use of high doses (>800U). The available evidence mainly referred to a single set of injections evaluating the efficacy and safety of the neurotoxin 30days after the treatment. In a prospective, non-randomized, open-label study, we studied the safety of repeated higher doses of incobotulinumtoxinA in post-stroke upper and lower limb spasticity...
July 15, 2017: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/28548676/the-diagnosis-and-management-of-chronic-migraine-in-primary-care
#7
Werner J Becker
BACKGROUND: Chronic migraine is common, affecting approximately 1% of the general population, and causes significant disability. OBJECTIVE: To summarize optimal involvement of primary care physicians in chronic migraine care, and to provide algorithms to assist them in the diagnosis and management of patients with chronic migraine. METHODS: An analysis of diagnostic and treatment needs in chronic migraine, based on a synthesis of the medical literature and clinical experience...
May 26, 2017: Headache
https://www.readbyqxmd.com/read/28536084/long-term-treatment-with-onabotulinumtoxina-results-in-consistent-durable-improvements-in-health-related-quality-of-life-in-patients-with-overactive-bladder
#8
David A Ginsberg, Marcus J Drake, Albert Kaufmann, Sidney Radomski, Angelo Gousse, Christopher J Chermansky, Andrew Magyar, Jean Paul Nicandro, Victor W Nitti
PURPOSE: To present the long-term effects of repeat onabotulinumtoxinA 100U treatment on health-related quality of life in overactive bladder patients with urinary incontinence who had an inadequate response to/were intolerant of an anticholinergic. MATERIALS AND METHODS: Patients completing either of two 24-week, phase III trials could enter a 3-year extension study and request multiple onabotulinumtoxinA 100U treatments as needed. Results for the I-QOL (Incontinence-Quality of Life) and KHQ (King's Health Questionnaire) are reported for upto 6 treatments...
May 20, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28505919/re-onabotulinumtoxina-vs-sacral-neuromodulation-on-refractory-urgency-urinary-incontinence-in-women-a-randomized-clinical-trial
#9
Alan J Wein
No abstract text is available yet for this article.
June 2017: Journal of Urology
https://www.readbyqxmd.com/read/28503231/onabotulinumtoxina-for-the-treatment-of-idiopathic-overactive-bladder-is-effective-and-safe-for-repeated-use
#10
Kevin Carlson, Andrea Civitarese, Richard Baverstock
INTRODUCTION: The objective of this study was to compare efficacy and safety outcomes between patients receiving onabotulinum-toxinA (OnabotA) for the first time and those receiving a repeat injection. METHODS: Data collected before and after OnabotA injection were extracted from a clinical registry. Patients were classified into either first or repeat injection subgroups. Efficacy was measured by the change in use of oral bladder medications, the number of voids per day or night, the frequency of urinary incontinence (UI) episodes, and patient-reported outcomes...
May 2017: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/28501541/characteristics-associated-with-treatment-response-and-satisfaction-in-women-undergoing-onabotulinumtoxina-and-sacral-neuromodulation-for-refractory-urgency-urinary-incontinence
#11
H E Richter, C L Amundsen, S W Erickson, J E Jelovsek, Y Komesu, C Chermansky, H S Harvie, M Albo, D Myers, W T Gregory, D Wallace
PURPOSE: To identify clinical and demographic characteristics associated with treatment response and satisfaction in women undergoing onabotulinumtoxinA and sacral neuromodulation therapies. MATERIAL AND METHODS: Data were analyzed from the Refractory Overactive Bladder: Sacral Neuromodulation vs Botulinum Toxin Assessment trial. Baseline participant characteristics and clinical variables associated with two definitions of treatment response: 1) reduction in mean daily urgency incontinence episodes over 6 months 2) ≥50% decrease in urgency incontinence episodes across 6 months were identified...
May 10, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28407394/efficacy-and-safety-of-onabotulinumtoxina-injection-in-patients-with-refractory-overactive-bladder-first-multicentric-study-in-turkish-population
#12
Kadir Onem, Omer Bayrak, Abdullah Demirtas, Burhan Coskun, Murat Dincer, Izzet Kocak, Rahmi Onur
AIMS: To investigate the efficacy and safety of intradetrusor onabotulinumtoxinA (onaBoNT-A) injection in patients with overactive bladder (OAB) refractory to antimuscarinic treatment. METHODS: A total of 80 patients with OAB symptoms were enrolled in this prospective multicenter study and received 100 U intradetrusor onaBoNT-A injection.The changes from baseline in the frequency of voiding, urge urinary incontinence (UI) and urge episodes, mean and maximum bladder capacities, uroflowmetry, post-void residual urine volume (PVR), quality of life score, and treatment benefit scale score were assessed...
April 13, 2017: Neurourology and Urodynamics
https://www.readbyqxmd.com/read/28394862/the-facial-platysma-and-its-underappreciated-role-in-lower-face-dynamics-and-contour
#13
Ada R T de Almeida, Alessandra Romiti, Jean D A Carruthers
BACKGROUND: The platysma is a superficial muscle involved in important features of the aging neck. Vertical bands, horizontal lines, and loss of lower face contour are effectively treated with botulinum toxin A (BoNT-A). However, its pars facialis, mandibularis, and modiolaris have been underappreciated. OBJECTIVE: To demonstrate the role of BoNT-A treatment of the upper platysma and its impact on lower face dynamics and contour. MATERIAL AND METHODS: Retrospective analysis of cases treated by an injection pattern encompassing the facial platysma components, aiming to block the lower face as a whole complex...
April 6, 2017: Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery [et Al.]
https://www.readbyqxmd.com/read/28389505/onabotulinumtoxina-injections-in-detrusor-facilitate-self-catheterisation-in-a-patient-with-paraplegia-and-bladder-outlet-dyssynergia
#14
François Hervé, Annick Viaene, Karel Everaert
This case report describes the case of improvement of clean intermittent catheterisation procedures after each intradetrusor administration of onabotulinumtoxinA in a 45-year-old man with L1 paraplegia with neurogenic detrusor overactivity and bladder outlet dyssynergia.On three occasions, improvement on clean intermittent catheterisation procedures appeared 10 to 14 days after intradetrusor injections of onabotulinumtoxinA and lasted for 9 months. We hypothesise a possible influence of intravesical injections of onabotulinumtoxinA on the storage reflex...
April 6, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/28388717/key-parameters-for-the-use-of-abobotulinumtoxina-in-aesthetics-onset-and-duration
#15
REVIEW
Mark Nestor, Glynis Ablon, Andy Pickett
Time to onset of response and duration of response are key measures of botulinum toxin efficacy that have a considerable influence on patient satisfaction with aesthetic treatment. However, there is no overall accepted definition of efficacy for aesthetic uses of botulinumtoxinA (BoNT-A). Mechanical methods of assessment do not lend themselves to clinical practice and clinicians rely instead on assessment scales such as the Frontalis Activity Measurement Standard, Frontalis Rating Scale, Wrinkle Severity Scale, and Subject Global Assessment Scale, but not all of these have been fully validated...
May 1, 2017: Aesthetic Surgery Journal
https://www.readbyqxmd.com/read/28387038/insights-into-the-functional-anatomy-behind-the-preempt-injection-paradigm-guidance-on-achieving-optimal-outcomes
#16
Andrew M Blumenfeld, Stephen D Silberstein, David W Dodick, Sheena K Aurora, Mitchell F Brin, William J Binder
OBJECTIVE: To provide clinically relevant insights on the identification of the muscles and techniques involved in the safe and effective use of onabotulinumtoxinA for chronic migraine prophylaxis. BACKGROUND: Although guidance on the use of onabotulinumtoxinA for chronic migraine is available, based on the Phase III Research Evaluating Migraine Prophylaxis Therapy (PREEMPT) clinical program, clinical experience has shown that insufficient understanding of the anatomy and function of the head and neck muscles may lead to undesirable outcomes and suboptimal efficacy...
May 2017: Headache
https://www.readbyqxmd.com/read/28382110/botulinum-toxin-in-the-management-of-chronic-migraine-clinical-evidence-and-experience
#17
REVIEW
Claus M Escher, Lejla Paracka, Dirk Dressler, Katja Kollewe
Chronic migraine (CM) is a severely disabling neurological condition characterized by episodes of pulsating unilateral or bilateral headache. The United States Food and Drug Administration (FDA) approved onabotulinumtoxinA (Botox(®)) for the prophylactic treatment of CM in 2010. It has been shown that onabotulinumtoxinA is effective in the reduction of headache frequency and severity in patients with CM. Treatment is well tolerated by the patients. This review reports on the history of botulinum neurotoxin (BoNT) in CM and presents the current clinical evidence for the use of onabotulinumtoxinA in the treatment of CM...
February 2017: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/28375973/incobotulinumtoxina-for-aesthetic-indications-a-systematic-review-of-prospective-comparative-trials
#18
Welf Prager, Diana Nogueira Teixeira, Phillip S Leventhal
BACKGROUND: IncobotulinumtoxinA is a botulinum toxin type A (BoNTA) indicated for temporary improvement in the appearance of upper facial lines with well-established efficacy and safety profiles. Whether incobotulinumtoxinA and other BoNTAs are equipotent is subject of debate. OBJECTIVE: To compare the efficacy of incobotulinumtoxinA and other BoNTAs for aesthetic applications. MATERIALS AND METHODS: PubMed and Embase were systematically searched for prospective clinical trials comparing incobotulinumtoxinA with onabotulinumtoxinA, abobotulinumtoxinA, or placebo for aesthetic applications...
April 3, 2017: Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery [et Al.]
https://www.readbyqxmd.com/read/28375917/urogenital-symptoms-in-neurologic-patients
#19
Jalesh N Panicker
PURPOSE OF REVIEW: Lower urinary tract and sexual dysfunction are commonly reported sequelae of neurologic disease and have a significant impact on quality of life. This article presents an up-to-date summary of the clinical presentation, investigations, and treatment options for urogenital dysfunction in patients with neurologic disease. RECENT FINDINGS: The pattern of lower urinary tract dysfunction is influenced by the site of the neurologic lesion. The risk for developing upper urinary tract damage is considerably less in patients with slowly progressive nontraumatic neurologic disorders, as compared to those with spinal cord injury or spina bifida...
April 2017: Continuum: Lifelong Learning in Neurology
https://www.readbyqxmd.com/read/28367260/a-single-blind-split-face-randomized-pilot-study-comparing-the-effects-of-intradermal-and-intramuscular-injection-of-two-commercially-available-botulinum-toxin-a-formulas-to-reduce-signs-of-facial-aging
#20
Priya Sapra, Shantel Demay, Sheetal Sapra, Julie Khanna, Kelli Mraud, Jennifer Bonadonna
Objective: To examine the effectiveness of intradermal botulinum toxin type A injection in improving skin texture and midface lift while reducing pore size and sebum production, as well as investigate the differences in effectiveness between onabotulinumtoxinA and abobotulinumtoxinA using intradermal and intramuscular injection methods. Design: A 16-week, single-blind, split-face, randomized study. Each patient served as their own control, receiving onabotulinumtoxinA and abobotulinumtoxinA randomized to either the left or right side of the face...
February 2017: Journal of Clinical and Aesthetic Dermatology
keyword
keyword
3072
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"